NZSG Equity Statement

Posted Sunday July 10, 2022

In 2021, NZSG called for expressions of interest to the EWG and was proud to welcome; Alex Lampton-Smith, Clarence Kerrison, James Irwin, Kirsty MacFarlane (Chair), Rachael Harry, and Tom Boswell as inaugural members.

Over the past eighteen months, the group have met to understand current equity strengths and challenges for gastroenterology in Aotearoa New Zealand. In line with work from similar speciality societies and Colleges and then DHBs and the Ministry of Health. The EWG focused on how our workforce can celebrate the amazing diversity it has, honour the Treaty of Waitangi and further build diversity and representation in priority areas.

The NZSG Equity Statement was published in May 2022 and shared with Clinical Leads, Trainees and the RACP:

Image by: NZ Gastro Office

Our Equity Statement acknowledges that equitable representation of Māori, Pasifika, female, and provincial gastroenterologists are shared priorities.

EWG agenda items have included mahi to create and share an understanding of equity with trainees, those that support them, and those that select them.

The EWG’s next step is presenting to the NZSG Executive An equity focus on selection of candidates to gastroenterology training in New Zealand. This will direct and guide equity priority areas into the Gastroenterology Advanced Registrar Training (MATCH) process from 2023 onwards. It is important to bring everyone along on this journey. This document will be shared with members for feedback and korero.

E tū ki te kei o te waka, kia pakia koe e ngā ngaru o te wā


Related Articles

2025 Advanced Gastroenterology Training Opportunities (Match 2024) Information

Tuesday April 2, 2024

NZSG will be accepting applications for placements from the 8th of April 2024. The final date for applying is Friday the...

Vacancies Events + 2 More

Read more »

NZCCRTGE - Conjoint Committee News

Friday March 15, 2024

The NZCCRTGE has made a few changes we'd like to let you know about


Read more »

Supply Issue Notice from Pharmac

Thursday February 15, 2024

We've received news about long-term supply issue affecting the Dipentum brand of olsalazine (250 mg capsules and 500 mg ...

News Pharma News

Read more »